Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

3.870 -0.090 (-2.27%)
Streaming Delayed Price Updated: 1:50 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 671,711
Open 4.000
Bid (Size) 3.870 (200)
Ask (Size) 3.880 (1,400)
Prev. Close 3.960
Today's Range 3.825 - 4.092
52wk Range 1.350 - 4.600
Shares Outstanding 22,506,956
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
From Natera, Inc.
Via Business Wire
News headline image
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+138.9%
+138.9%
1 Month
-0.5%
-0.5%
3 Month
+32.5%
+32.5%
6 Month
+146.5%
+146.5%
1 Year
+40.7%
+40.7%

More News

Read More
News headline image
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Inc (NASDAQ:ELDN) Reports Narrower Q4 Loss and Positive Clinical Data for Tegoprubart ↗
Via Chartmill
News headline image
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering
Via MarketMinute
Topics Initial Public Offering Intellectual Property Regulatory Compliance
News headline image
Top movers in Wednesday's pre-market session ↗
Via Chartmill
News headline image
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
Via MarketMinute

Frequently Asked Questions

Is Eledon Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Eledon Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Eledon Pharmaceuticals, Inc. - Common Stock trade on?
Eledon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock is ELDN on the Nasdaq Stock Market
What is the current price of Eledon Pharmaceuticals, Inc. - Common Stock?
The current price of Eledon Pharmaceuticals, Inc. - Common Stock is 3.870
When was Eledon Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Eledon Pharmaceuticals, Inc. - Common Stock was at 06/25/26 01:50 PM ET
What is the market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock is 87.10M
How many shares of Eledon Pharmaceuticals, Inc. - Common Stock are outstanding?
Eledon Pharmaceuticals, Inc. - Common Stock has 87M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.